trenibotulinumtoxinE

TrenibotulinumtoxinE (TrenibotE) is a first-in-class botulinum neurotoxin serotype E developed for the treatment of moderate to severe glabellar lines (frown lines between the eyebrows). Unlike traditional botulinum toxin type A products (such as onabotulinumtoxinA/BOTOX), TrenibotE is characterized by a rapid onset of action—clinical effects can be observed as early as 8 hours after administration—and a shorter duration of effect lasting approximately 2–3 weeks. This profile may address concerns among new patients about unnatural or prolonged results from aesthetic neurotoxins. The drug acts primarily by inhibiting acetylcholine release at neuromuscular junctions through SNARE protein antagonism and also exhibits glutamate antagonism and neuromuscular blocking activity. Developed originally by Bonti and further advanced by AbbVie/Allergan Aesthetics, TrenibotE has completed pivotal Phase 3 trials with positive results for efficacy and safety in over 2,100 patients[1][4][5][7][8].

Brand names

TrenibotE

Other names

botulinum toxin E